Open Heart

NOVEMBER 8, 2023

A network meta-analysis aimed to compare effects of both conventional and alternative drug combinations on time to develop primary composite outcome of cardiovascular death or heart failure hospitalisation (PCO). Methods Randomised controlled trials (RCTs) were identified from Medline, Scopus up to June 2021.

Heart Failure 52

Heart Failure ACE Inhibitor Outcomes Pharmacology 52

Heart BMJ

JANUARY 10, 2024

Renin–angiotensin system (RAS) inhibitors could potentially improve cardiac remodelling and clinical outcomes after SAVR. The primary outcome was major adverse cardiovascular events (MACEs; all-cause mortality, stroke or myocardial infarction). Both treatment with ACE inhibitors (aHR 0.89 (95% CI 0.82

Aortic valve 40

Aortic valve Aortic ACE Inhibitor Stenosis 40

DAIC

APRIL 6, 2024

Researchers tracked outcomes for a median of just under 18 months. All secondary endpoints related specifically to heart failure outcomes were significantly reduced among patients who received empagliflozin. The study’s primary composite endpoint occurred in 8.2% of those who received empagliflozin and 9.1% of the control group.

Heart Attack 98

Heart Attack Heart attacks Heart Failure Outpatient 98

Heart BMJ

MARCH 12, 2024

The aim of this study was to evaluate in a network meta-analysis if beta-blockers (BB) and ACE inhibitors/angiotensin receptor blockers (ACEi/ARBs), in combination or not, can effectively prevent TTS recurrences. The primary outcome was TTS recurrence.

ACE Inhibitor 52

ACE Inhibitor Heart Failure Outcomes 52

Conquering CHD

JUNE 20, 2023

ACE Inhibitors WHAT THEY DO : ACE inhibitors block the angiotensin-converting enzyme (ACE) which causes narrowing of blood vessels. COMMON NAMES : Some common brand name ACE inhibitor drugs available to patients with CHD include lisinopril, ramipril and enalapril.

Congenital Heart Disease 52

Congenital Heart Disease Congenital Heart Disease ACE Inhibitor 52

Open Heart

FEBRUARY 17, 2024

were on ACE inhibitors/angiotensin receptor blockers and 54.9% Sociodemographic characteristics also played a role on the outcome, which can be targeted when planning interventions to improve outcomes. Results A total of 237 participants were included in the final analysis. The mean age was 61.3±17.36

Heart Failure 40

Heart Failure Quality of Life ACE Inhibitor COVID-19 40

European Journal of Heart Failure

NOVEMBER 29, 2023

Methods and results Patients ( n  = 5661) included in the PARADISE MI trial (Prospective ARNI vs. ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After MI) were stratified according to MRA. Primary outcomes in this substudy were worsening heart failure or cardiovascular death.

Myocardial Infarction 40

Myocardial Infarction ACE Inhibitor Heart Failure Pulmonary 40

The British Journal of Cardiology

JULY 17, 2024

These trials added weight to the evidence that supported the use of both angiotensin-converting enzyme inhibitors (ACEi) or ARBs in diabetic kidney disease and chronic kidney disease (CKD), particularly in patients with proteinuria.

Kidney Disease 40

Kidney Disease Outcomes Diabetes Heart Failure 40

Dr. Malcolm Kendrick

OCTOBER 20, 2023

20th October 2023 (With lessons from, and for, all other health services around the world) The Quality and Outcomes Framework The Quality and Outcomes Framework (QOF) was to be the glittering triumph of Evidence Based Medicine. Many of the commonest and most deadly diseases afflicting humanity would be picked up early, then treated.

Heart Attack 52

Heart Attack Heart attacks Blood Pressure ACE Inhibitor 52

Dr. Smith's ECG Blog

NOVEMBER 15, 2023

associated typical Myocardial Infarction therapies such as statins and ACE inhibitors with significantly decreased 1 year mortality in MINOCA patients, which suggests that they do indeed have a similar pathophysiology to MI patients with obstructive coronary disease. Lindahl et al. References: 1. Lindahl B, Baron T, Erlinge D, et al.

Coronary Angiogram 109

Coronary Angiogram Plaque Thrombosis STEMI 109

Dr. Sanjay Gupta

MARCH 6, 2022

If we are unable to build a relationship of trust with the patient then we are going to fail in achieving the best outcome for that patient and this is why engagement and empathy are so essential. Secondly all management should be ensconced in kindness, patience, connection and good communication.

Chronic Disease 40

Chronic Disease Quality of Life Heart Failure Nursing 40

Dr. Smith's ECG Blog

NOVEMBER 30, 2022

associated typical Myocardial Infarction therapies such as statins and ACE inhibitors with significantly decreased 1 year mortality in MINOCA patients, which suggests that they do indeed have a similar pathophysiology to MI patients with obstructive coronary disease. Lindahl et al. References: 1. Lindahl B, Baron T, Erlinge D, et al.

Plaque 52

Plaque Chest Pain Thrombosis Stenosis 52

Open Heart

DECEMBER 2, 2024

Methods HFrEF patients with symptomatic LVEF≤35% despite ACE inhibitor/beta blocker/mineralocorticoid receptor antagonist therapy, and qualified for sacubitril/valsartan switchover were recruited to this single centre prospective study. Clinical, volumetric and outcome data were collected and compared.

ACE Inhibitor 52

ACE Inhibitor Heart Failure Cardiomyopathy Outcomes 52